Liof Pharma

Liof Pharma is a private, revenue-generating CDMO founded in 2019, leveraging over 15 years of team experience in the European biopharmaceutical manufacturing sector. The company's core business is providing flexible, small-to-medium scale aseptic fill-finish and lyophilization services for high-value sterile injectables, catering primarily to oncology and other therapeutic areas. It differentiates itself through regulatory compliance, a 'right-first-time' approach, and integrated services spanning formulation, quality control, and cold-chain logistics. Liof Pharma acts as a strategic manufacturing partner for biotechs and pharma companies aiming to accelerate clinical development and market entry.

Aseptic fill-finish and lyophilization platform for sterile injectable biologics (peptides, proteins, mAbs, RNA, AAV vectors), operating under international GMP standards with integrated QC and cold-chain logistics.

Liof Pharma competes in a crowded CDMO market against large global players (e.g., Lonza, Catalent) and many specialized European firms. Its differentiation lies in its focused expertise on small-to-medium scale aseptic fill-finish and lyophilization for high-value biologics, combined with regulatory agility and a client-centric approach.